News
Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market
As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm behind its approved Duchenne muscular dystrophy (DMD) treatment. | As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head,
Sarepta to continue shipping gene therapy despite patient deaths
Sarepta Therapeutics said it will continue shipping its gene therapy Elevidys for Duchenne muscular dystrophy patients despite an FDA request to pause distribution following multiple patient deaths. The FDA’s request July 18 came after Sarepta confirmed the death of a third patient from acute liver failure tied to its gene therapy programs.
The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb girdle ...
Ocugen has dosed the first subject in its Phase II/III GARDian3 trial of modifier gene therapy candidate, OCU410ST ...
A team of Chinese medical experts say they can produce anti-cancer cells directly inside the human body using gene therapy ...
Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an ...
Our Bureau, Mumbai Friday, July 18, 2025, 17:45 Hrs [IST] ...
The Centers for Medicare and Medicaid Services (CMS) has selected 35 participants for its new, voluntary Cell and Gene ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback